Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
31.16
-0.04 (-0.13%)
Jun 27, 2025, 4:00 PM - Market closed
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Supernus Pharmaceuticals stock have an average target of 36, which predicts a 15.53% increase from the current stock price of 31.16.
Price Target: $36.00 (+15.53%)
Analyst Consensus: Hold
* Price targets were last updated on Feb 26, 2025.
Analyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $36 | Hold | Reiterates | $36 | +15.53% | Feb 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades $57 → $36 | Buy → Hold | Downgrades | $57 → $36 | +15.53% | Feb 19, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $41 → $36 | Buy → Hold | Downgrades | $41 → $36 | +15.53% | Sep 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $45 → $41 | Buy | Maintains | $45 → $41 | +31.58% | Feb 28, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $43 | Buy | Maintains | $42 → $43 | +38.00% | Nov 9, 2023 |
Financial Forecast
Revenue This Year
644.74M
from 661.82M
Decreased by -2.58%
Revenue Next Year
722.25M
from 644.74M
Increased by 12.02%
EPS This Year
1.73
from 1.32
Increased by 31.11%
EPS Next Year
2.41
from 1.73
Increased by 39.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 693.0M | 861.0M | 1.0B | ||
| Avg | 644.7M | 722.3M | 805.8M | ||
| Low | 608.0M | 648.7M | 715.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.7% | 33.5% | 38.9% | ||
| Avg | -2.6% | 12.0% | 11.6% | ||
| Low | -8.1% | 0.6% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.21 | 2.82 | 3.83 | ||
| Avg | 1.73 | 2.41 | 3.44 | ||
| Low | 1.08 | 1.96 | 2.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 67.0% | 63.2% | 59.0% | ||
| Avg | 31.1% | 39.3% | 42.9% | ||
| Low | -18.3% | 13.3% | 17.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.